The efficacy of treatment with albendazole.
Albendazole, a benzimidazole derivative, was administered as a single dose of either 400 mg or 600 mg to two groups to ascertain the efficacy, tolerance and safety of the regimens. At a dose of 400 mg, a cure rate 35/36 (97%) against Ascaris was found. At 600 mg, the cure rate was 21/30 (70%), significantly lower than the 400 mg rate. Against Trichuris, albendazole at 400 mg had a cure rate of 21/48 (44%), at 600 mg there was a cure rate of 29/43 (67%). Mild side effects were noted in 7 individuals. Whether the moderate increase in efficacy against Trichuris and the loss of efficacy against Ascaris improves the cost:benefit ratio must be left to the prescriber of the drug.
Hanjeet
K
K
Department of Parasitology, Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia.
Mathias
R G
RG
D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy*; D002648:Child; D005260:Female; D006725:Hookworm Infections / Q000188:drug therapy*; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014257:Trichuriasis / Q000188:drug therapy*
D015766:Albendazole